Get the latest news, insights, and market updates on MGX (Metagenomi, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Metagenomi to Present at Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A, President and Chief Executive Officer of Metagenomi, will be presenting at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:30 a.m. GMT. A live webcast will be available in the inv Nov 17, 2025 - $MGX
Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 11, 2025 - $MGX
Metagenomi: Q3 Earnings Snapshot
EMERYVILLE, Calif. AP) — Metagenomi Inc. MGX) on Tuesday reported a loss of $20.4 million in its third quarter. Nov 11, 2025 - $MGX
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001 hemophilia A program; pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA submissions expected in 4Q 2026 Organizational restructuring reduced workforce by 25%; Capital allocation strategy anticipated to extend cash runway into the 4Q 2027 Jian Irish, Ph.D., M.B.A., currently Pr Nov 11, 2025 - $MGX
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding data from t Nov 11, 2025 - $MGX
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 5, 2025 - $MGX
Metagenomi taps Amazon's custom chips to develop gene-editing tools
SAN FRANCISCO (Reuters) -Biotech firm Metagenomi said it is using artificial intelligence chips from Amazon.com's cloud computing unit to power some of its work in developing gene-editing technologies. The work represents one of the first major uses of Amazon Web Services chips beyond chatbots and other products powered by large language models, with Metagenomi saying AWS's Inferentia chips had proven far more cost-effective than products from rivals like Nvidia. Emeryville, California-based firm Metagenomi is one of a number of companies working to develop tools to inject genetic material into the human body where it can edit genes to treat diseases. Oct 22, 2025 - $MGX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple